The neonatal Fc receptor (FcRn) is a cellular receptor that transports immunoglobulin G (IgG) across tissue barriers and protects IgG and serum albumin from intracellular degradation. Its name reflects its original identification in neonatal rodents, where it transfers maternal antibodies from milk across the intestinal lining. FcRn also functions throughout adult life, helping determine the concentrations and persistence of these abundant blood proteins. Its defining property is pH-dependent binding: it captures its cargo in acidic intracellular compartments and releases it when exposed to the near-neutral conditions outside cells.
Molecular structure
FcRn is a heterodimer consisting of a membrane-spanning heavy chain and the smaller protein β2-microglobulin. In humans, the heavy chain is encoded by the FCGRT gene. It has three extracellular domains, a transmembrane segment, and a cytoplasmic tail containing signals that influence intracellular trafficking.
The receptor is structurally related to major histocompatibility complex class I molecules. Unlike classical class I molecules, however, it does not present peptide antigens to T cells. Its principal established functions concern protein transport and preservation.
FcRn recognizes the Fc region of an antibody, rather than the antigen-binding tips. Its IgG-binding site lies at the interface between the antibody’s second and third constant heavy-chain domains. Albumin binds to a distinct surface on FcRn, allowing the receptor to interact with IgG and albumin simultaneously.
Although FcRn belongs to the broader family of Fc-binding receptors, it differs from conventional Fcγ receptors. Those receptors primarily connect antibody recognition to cellular effector functions, whereas FcRn principally controls antibody trafficking and persistence.
pH-dependent recycling
FcRn preserves circulating proteins through a repeated cycle of uptake, binding, sorting, and release.
- Uptake: Cells internalize extracellular fluid and its dissolved proteins, including IgG and albumin, through endocytosis.
- Acidification: Internalized material enters endosomes, whose interiors become acidic.
- Cargo capture: At approximately pH 6, FcRn binds IgG and albumin.
- Sorting: Receptor-bound cargo is directed toward recycling or transport pathways rather than being delivered to lysosomes for degradation.
- Release: At the cell surface, exposure to an extracellular pH of approximately 7.4 greatly weakens binding, releasing the cargo.
The pH sensitivity of IgG binding depends partly on changes in the protonation of amino-acid residues at the receptor–antibody interface, including histidines. The binding interaction therefore couples the chemical conditions within a compartment to the destination of the protein.
This “salvage” mechanism contributes to the unusually long circulating half-lives of IgG and albumin. Many human IgG antibodies persist for roughly three weeks, although the value varies with antibody subclass, molecular properties, and physiological circumstances. FcRn rescue is not unlimited: when available receptor capacity becomes insufficient relative to the amount of cargo, a greater fraction escapes rescue and is degraded.
Recycling returns cargo to the same side of a cell from which it entered. By contrast, transcytosis carries cargo across a cell to the opposite surface. FcRn can participate in both processes, depending on cell type and tissue organization.
Maternal antibody transfer
FcRn provides an important route for transferring maternal antibodies to offspring, establishing temporary passive immunity before the offspring’s own immune responses are fully developed.
The dominant route differs among mammals:
- In humans, maternal IgG transfer occurs predominantly across the placenta before birth. FcRn in the placental syncytiotrophoblast participates in moving IgG from maternal blood toward the fetal circulation. Transfer increases substantially during later pregnancy.
- In rodents, FcRn-mediated uptake of milk-derived IgG across the neonatal intestine is especially prominent. This intestinal transport system gave the receptor its name.
The name therefore does not imply that FcRn is restricted to newborns or that human infants obtain most systemic maternal IgG by the same route as neonatal rodents. Human breast milk contains substantial secretory IgA, whose transport into milk involves a different receptor system.
Maternal IgG transfer supplies antibodies against infectious agents, but it is not intrinsically selective for beneficial antibodies. Maternal autoantibodies can also cross the placenta and contribute to certain antibody-mediated neonatal disorders.
Functions in adult tissues
FcRn is expressed in several epithelial and endothelial tissues and in immune cells, including macrophages and dendritic cells. Much of the receptor resides inside cells rather than continuously on the cell surface.
Its adult functions include:
Maintenance of circulating proteins. FcRn reduces the degradation of IgG and albumin, helping maintain their abundance in blood and tissues. Albumin preservation is important because albumin contributes to plasma oncotic pressure and transports numerous small molecules.
Antibody distribution across barriers. FcRn can transport IgG across epithelial surfaces. The direction and extent of transport depend on tissue-specific trafficking pathways, receptor expression, and local conditions.
Handling of immune complexes. In some antigen-presenting cells, FcRn influences the intracellular processing of IgG-containing immune complexes. This can affect antigen presentation and subsequent immune responses. These activities depend on the cellular context and are distinct from the direct peptide-presentation function of classical MHC molecules.
FcRn should consequently be understood as a regulator of protein movement and survival, not simply as a neonatal intestinal uptake receptor.
Therapeutic significance
Extending antibody persistence
FcRn binding is an important consideration in the design of therapeutic antibodies. Changes to the antibody Fc region can enhance binding at acidic pH while preserving release at near-neutral pH. Suitable modifications can increase recycling and extend circulating persistence.
Stronger binding alone is not necessarily advantageous. If an engineered antibody binds too strongly under extracellular conditions, inefficient release can undermine the expected benefit. Antibody clearance also depends on factors outside FcRn recycling, including target binding, molecular charge, aggregation, and immune responses against the therapeutic protein.
Albumin-binding strategies and albumin fusion proteins can likewise exploit albumin’s FcRn-dependent preservation to prolong the persistence of attached therapeutic molecules.
Blocking IgG recycling
FcRn inhibition has the opposite purpose: reducing circulating IgG, including pathogenic autoantibodies. Blocking the interaction between IgG and FcRn increases the fraction of internalized IgG delivered for degradation.
Efgartigimod, an engineered Fc fragment, and rozanolixizumab, a monoclonal antibody against FcRn, are examples of medicines that use this mechanism. Both have received authorization for specified forms of generalized myasthenia gravis.
This approach is not specific to an individual disease-causing antibody. It lowers a broader pool of IgG, including protective antibodies, while not directly eliminating the cells that produce them. Effects on albumin depend on the inhibitor’s binding properties and mechanism; interference with IgG salvage does not necessarily produce an equivalent effect on albumin salvage.
Research considerations and limitations
FcRn interactions differ among species. Human IgG can interact differently with human and rodent receptors, so results from ordinary mouse models do not always predict antibody persistence in humans. Models expressing human FcRn help investigate these differences but do not reproduce every aspect of human physiology.
Likewise, a receptor-binding measurement alone does not fully predict biological behavior. Binding at acidic and neutral pH, intracellular sorting, receptor abundance, tissue access, and competition with endogenous proteins all affect the final outcome. Studies of FcRn therefore combine structural and biochemical measurements with cell-based transport experiments and investigations of protein distribution and clearance in whole organisms.